Sector Update: Healthcare Stocks Fall Late Afternoon

03:48 PM EDT, 09/08/2026 (MT Newswires) -- Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%. The iShares Biotechnology ETF (IBB) shed 1.9%. In corporate news, Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "material impact" from a recent cybersecurity incident. Boston Scientific shares were down 5%. Novartis (NVS) shares fell past 13% after it said a phase 3 trial assessing delpacibart etedesiran in people with myotonic dystrophy type 1 failed to meet its primary endpoint. GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding for its $10.6 billion takeover of Nuvalent, Bloomberg reported. GSK shares fell 2.4%. Novo Nordisk (NVO) has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported. The trials, which tested the drug in heart failure patients, will end early, the company told MT Newswires. It added that patients will continue through to their 3-months follow-up as already planned. Novo shares were shedding 2.7%.